Core Viewpoint - Hubei province is leveraging its educational resources and alumni network to drive innovation, talent acquisition, and economic development through the "Alumni Return" initiative, aiming to attract over 3,000 alumni talents and establish more than 30 innovation incubation bases by 2027 [1][2]. Group 1: Alumni Return Initiative - The "Alumni Return" initiative is designed to transform Hubei's educational advantages into innovation and development strengths, focusing on technology, industry, and emotional connections [1]. - The initiative includes five special actions and 20 specific measures to address the challenges of alumni returning, staying, and thriving in Hubei [2]. Group 2: Special Actions - The "Alumni + Intelligence" action aims to establish a comprehensive alumni service organization and a big data service platform to attract alumni talents [2][3]. - The "Alumni + Technology" action encourages alumni enterprises to participate in major national innovation platforms and support advanced manufacturing and modern service industry clusters [3]. - The "Alumni + Projects" action focuses on attracting investments from top enterprises and alumni projects to Hubei, utilizing platforms like the Chushang Conference [3]. - The "Alumni + Enterprises" action promotes collaboration among alumni enterprises and supports innovation through seed funds and government investment [4]. - The "Alumni + Education" action supports partnerships between alumni enterprises and educational institutions to cultivate skilled talents [4]. Group 3: Support Measures - The initiative includes optimizing government services, resource guarantees, incentive mechanisms, and emotional connections to enhance support for returning alumni [4]. - Regular "Alumni Return Conferences" and related activities will be organized to facilitate investment and technology transfer [4][5]. Group 4: Innovation and Development Goals - Hubei aims to strengthen innovation platforms and talent pipelines for alumni enterprises, fostering a range of high-growth alumni businesses [5]. - The province plans to achieve breakthroughs in key technologies and products by 2025, integrating alumni enterprises into major industry innovation frameworks [5]. - Efforts will be made to enhance the synergy between technological and industrial innovation, promoting a supportive ecosystem for alumni enterprises [5][6].

《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、 无锡市德科立光电子技术股份有限公司监事会 关于 2023 年限制性股票激励计划首次授予部分第一个 归属期归属名单的核查意见 无锡市德科立光电子技术股份有限公司（以下简称"公司"）监事会根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称" 《证券法》"）、 《科创板上 市公司自律监管指南第 4 号——股权激励信息披露》等法律、法规和规范性文件 和《公司章程》的有关规定，对公司 2023 年限制性股票激励计划（以下简称"本 次激励计划"）首次授予第一个归属期符合归属条件的激励对象名单进行审核， 发表核查意见如下： 经核查，本次激励计划拟归属的 323 名激励对象绩效考核结果合规、真实， 不存在虚假、故意隐瞒等相关情况，符合《公司法》《证券法》等法律、法规和 规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》 等法律、法规和规范性文件规定的激励对象条件，符合公司《2023 年限制性股 票激励计划（草案）》规定的激励对象范围，其作为公司本次激励计划激励对象 的主体资格合法、有效，激励对象获授限 ...

A 股每股现金红利0.85元 证券代码：603297 证券简称：永新光学 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/13 | － | 2025/6/16 | 2025/6/16 | | ? 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经宁波永新光学股份有限公司（以下简称"公司"）2025 年 5 月 20 日 的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，扣除拟回购注销的限制性股票 213,800 股 后，在中国证券登记结算有限责任公司上海分公司（以下简称"中国结算上海分公司"）登记 在册的本公司全体股东。 根据公司 2024 年年度股东大会审议通过的《2024 年度利润分配 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Group 1 - The public fund industry continues to focus on high-intensity research, particularly in hard technology and pharmaceuticals, with 123 public fund institutions conducting 662 research sessions on 112 A-shares in the first week of June [1] - The optical and optoelectronic industry, represented by Hongjing Optoelectronics (301479), received the most attention, with over 20% of public fund institutions participating in 36 research sessions [1] - A total of 22 secondary industries received at least 10 research sessions, indicating a concentrated interest in specific sectors [1] Group 2 - The optical and optoelectronic industry had the highest research activity, with 7 stocks collectively receiving 72 sessions, followed by the chemical pharmaceutical industry with 59 sessions across 6 stocks [2] - The jewelry industry saw a notable increase in attention, with companies like Cuihua Jewelry and Mankalon receiving a total of 46 research sessions [2] - Public fund institutions are increasingly focusing on technology, pharmaceuticals, and consumer upgrades, reflecting current market conditions [2] Group 3 - Yifan Pharmaceutical (002019) discussed its innovative drug development during institutional research, emphasizing the importance of cautious and rational approaches to R&D, particularly for First-in-Class (FIC) drugs [3] - The company is prioritizing the development of its drug F-652 for alcohol-related liver disease in collaboration with U.S. research institutions, while also evaluating risks and opportunities [3] - Yifan Pharmaceutical is also advancing early-stage products like IL-15 fusion protein, which are still in the early research phase [3]

Group 1 - The core viewpoint of the article highlights the significant progress in the development of high-tech industries in national high-tech zones, with specific emphasis on the emergence of new industries and original technologies [1][2] - The national high-tech zones achieved an industrial added value of 1.7 trillion yuan in the first quarter of this year, representing a year-on-year growth of 7.1% [1] - Key regions such as Zhongguancun in Beijing, Zhangjiang in Shanghai, and Donghu in Wuhan are leading in their respective sectors, with the integrated circuit industry in Shanghai accounting for 20% and the optoelectronic information industry in Wuhan accounting for 50% of the national scale [1][2] Group 2 - The Ministry of Industry and Information Technology plans to enhance the competitive advantages of national high-tech zones by focusing on their unique strengths and fostering emerging industries [2] - By the end of 2024, national high-tech zones are expected to host 33% of the country's high-tech enterprises, 46% of specialized and innovative "little giant" enterprises, and 67% of unicorn companies [2][3] - The government aims to cultivate world-class enterprises and technology leaders, increasing support for "gazelle" and unicorn companies to further invigorate the development of high-tech industries [3]

2025 年 06 月 08 日 北证专精特新（899601）：小而精， 特色更鲜明的优质投资标的 ——北交所发布北证专精特新指数点评 证券分析师 刘靖 A0230512070005 liujing@swsresearch.com 研究支持 吕靖华 A0230124070002 lvjh@swsresearch.com 联系人 吕靖华 (8621)23297818× lvjh@swsresearch.com 策 略 研 究 证 本研究报告仅通过邮件提供给 中庚基金 使用。1 请务必仔细阅读正文之后的各项信息披露与声明 A 股 策 资料来源：Wind，申万宏源研究；截至 2025/6/6 资料来源：Wind，申万宏源研究；截至 2025/6/6 略 券 研 究 报 告 ⚫ 事件：2025 年 6 月 6 日，北交所公告将于 2025 年 6 月 30 日正式发布北证专精特新指 数，经流动性筛选后，北证专精特新指数将从符合条件的北交所专精特新"小巨人"上市 公司中选取市值最大的 50 只作为指数样本，为市场提供多维度投资标的和业绩基准。 ⚫ 北证专精特新聚焦小巨人、特色更鲜明，编制规则采用半年度调仓、调整数量不超 ...

公司如何看待 LCD行业供需情况？行业面板厂商坚持"按需生产"的经营策略，需求端库存实现加速去化，产业库存趋近健康标准，行业需求归正 常节奏。中国大陆将成为确定性市场，能够以较高的确定性对冲国际贸易环境变化的不确定性。 公司如何看待 LCD产品价格趋势？根据咨询机构数据及分析，得益于良好的终端需求，LCD TV主流尺寸面板价格自2025年1月起全面上涨并延续 至3月；进入二季度，LCD TV 面板采购需求预计逐步降温，5月LCD TV 产品价格维持稳定。LCD IT方面，MNT 面板价格保持温和上涨态势， NB面板价格整体维持稳定。 柔性 AMOLED业务进展？公司在柔性 MOLED 领域多年布局，已经构建起产能规模和技术优势，并积累了较好的客户资源，在柔性MOLED领域 全面覆盖手机主要 Top品牌客户，同时积极布局车载、IT等中尺寸创新应用，匹配下游客户需求。未来，公司将持续强化自身的产品和技术能 力，稳步提升柔性 MOLED业务整体竞争力。 公司投建的第 6代 AMOLED生产线项目进度？5月20日，公司成都第8.6代MOLED生产线项目提前4个月开始工艺设备搬入，标志着该产线由建设 阶段开始向产线运营 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688301 证券简称：奕瑞科技 公告编号：2025-037 转债代码：118025 转债简称：奕瑞转债 奕瑞电子科技集团股份有限公司 关于实施2024年年度权益分派时可转债转股 价格调整暨转股连续停牌的提示性公告 本次权益分派方案实施后，公司将依据《上海奕瑞光电子科技股份有限公司向不特定对象发行可转换公 司债券募集说明书》中所载的发行条款及相关规定，对"奕瑞转债"当期转股价格进行调整。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 证券停复牌情况：适用 因实施2024年年度权益分派，奕瑞电子科技集团股份有限公司（以下简称"公司"）的相关证券停复牌情 况如下：权益分派公告日前一交易日（2025年6月12日）至权益分派股权登记日期间，公司可转债将停 止转股。 ■ 注：停牌终止日及复牌日可在本公司后续发布的可转债转股价格调整公告中查阅。 一、2024年年度权益分派方案的基本情况 公司2024年年度利润分配方案为：公司2024年年度拟以实施权益分派股权 ...

Core Points - The legal opinion letter confirms the legality and validity of the 2024 annual shareholders' meeting of Wuhan Changying Tongguang Technology Co., Ltd. [3][5][8] - The meeting was convened by the company's board of directors and followed the required legal procedures [5][6][10] - The voting results showed a high approval rate for the proposed resolutions, indicating strong shareholder support [10][12][17] Group 1: Meeting Procedures - The shareholders' meeting was announced on May 17, 2025, with a notice period of 20 days before the meeting [5][6] - The meeting took place on June 6, 2025, using a combination of on-site and online voting methods [6][8] - The meeting was presided over by a designated director due to the online participation of the chairman [6][8] Group 2: Attendance and Voting - A total of 58 shareholders participated in the voting, representing 50,801,889 shares, which is 42.5980% of the total voting shares [7][10] - The voting results indicated that 99.9405% of the votes were in favor of the resolutions, with minimal opposition [10][12][17] - The resolutions included the annual report, financial statements, and profit distribution plan, among others [8][10] Group 3: Legal Compliance - The legal opinion confirms that all procedures, including the qualifications of the conveners and attendees, complied with relevant laws and regulations [4][5][17] - The opinion letter emphasizes that the firm conducted thorough verification to ensure the accuracy and legality of the meeting [4][5] - The resolutions passed were within the authority of the shareholders' meeting and aligned with the previously announced agenda [8][10]